The new REMS strategy calls for drug manufacturers to offer opioid education programs to prescribers and create FDA-approved patient education materials that address the safe use of the drugs — a development that the AAPM calls a “huge leap forward.”
“Through proper education and training, opioids can be administered safely to patients and continue to be an important option in the treatment of chronic and debilitating pain that is suffered by millions of Americans,” the organization said in a prepared statement. The AAPM also plans to issues a series of best practices for patients and prescribers to further address proper opioid use.
Related Articles on Pain Management:
Humira Relieves Spinal Arthritis Pain, Study Says
Dr. Catherine Bushnell to Lead New NIH Multidisciplinary Pain Program
ASIPP Releases Opioid Guidelines
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.